drugset / Trial / NCT00503724
Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
Phase 1
Completed
32 enrolled
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin in treating young patients with refractory primary brain tumors.
Timeline
- Start
- 2007-06
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | enzastaurin | Small molecule | 200 mg/m2 | Oral |
| Subject | enzastaurin | Small molecule | 260 mg/m2 | Oral |
| Subject | enzastaurin | Small molecule | 340 mg/m2 | Oral |
| Subject | enzastaurin | Small molecule | 440 mg/m2 | Oral |